CG Oncology (CGON) Research & Development (2023 - 2026)

CG Oncology's Research & Development history runs 4 years deep, the most recent figure standing at $43.7 million for Q1 2026.

• Quarterly Research & Development rose 59.21% year-over-year to $43.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132.9 million (up 43.9% YoY) and the FY2025 annual result came in at $116.6 million, up 42.07% from the prior year.
• Research & Development was $43.7 million for Q1 2026 at CG Oncology, up from $30.0 million in the prior quarter.
• Across five years, Research & Development topped out at $43.7 million in Q1 2026 and bottomed at $7.8 million in Q1 2023.
• A 4-year average of $22.2 million and a median of $19.6 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development surged 119.46% — and 2025, when it climbed 11.78%.
• CG Oncology's Research & Development stood at $16.3 million in 2023, then surged by 64.01% to $26.8 million in 2024, then gained by 11.78% to $30.0 million in 2025, then soared by 45.97% to $43.7 million in 2026.
• Business Quant data shows CGON's Research & Development at $43.7 million in Q1 2026, $30.0 million in Q4 2025, and $27.9 million in Q3 2025.